MustGrow Biologics Corp. Secures $2 Million in Non‑Brokered Private Placement

Saskatoon, Saskatchewan – In a decisive move to accelerate the commercialization of its proprietary AllylIsothiocyanate (AITC) platform, MustGrow Biologics Corp. (TSXV: MGRO) announced the successful closing of a $2 million non‑brokered private placement on 23 January 2026. The offering consisted of 4 million units, each comprising one common share and one common share purchase warrant. Units were priced at $0.50, yielding gross proceeds of $2 million, with net proceeds earmarked for critical inventory expansion and working capital.

Allocation of Proceeds

  • TerraSante™ Production – MustGrow will deploy capital to scale manufacturing of TerraSante™, its mustard‑derived organic biofertility product, which has already attracted validation from leading agribusinesses.
  • NexusBioAg Distribution – Inventory for agricultural products sold through the company’s Canadian distribution platform, NexusBioAg, will be bolstered to meet anticipated demand.
  • General Corporate Purposes – Remaining funds will support broader operational and strategic initiatives, including regulatory compliance and market expansion.

Warrant Structure

Each unit includes a warrant exercisable for 60 months at an exercise price of $0.70, enabling investors to purchase additional shares at a premium to the offering price. Finders who introduced investors were compensated with cash fees and 210,000 non‑transferable warrants (6 % of issued shares), further aligning incentives across the investment community.

Market Context

The timing of this funding aligns with a broader shift in the agritech sector. In early 2026, the Mercosur trade agreement is poised to impose stricter limits on synthetic pesticides, creating a window for biological alternatives. MustGrow’s AITC platform—effective against nematodes, soil‑borne diseases, and other soil pests—positions the company as a strategic technology provider in this emerging landscape. Analysts note that major players such as Bayer, Novo Nordisk, and BioNxt are increasingly integrating bio‑based solutions, underscoring the commercial viability of MustGrow’s product pipeline.

Forward Outlook

With the capital influx, MustGrow is set to accelerate the production of its flagship products, expand its Canadian distribution footprint, and position itself to capture market share in regions moving away from synthetic agrochemicals. The company’s strong valuation metrics (price‑to‑earnings ratio of –7.47) and recent 52‑week price range (CAD 0.5–1.52) suggest significant upside potential as demand for sustainable agricultural inputs rises.

As the global agricultural industry navigates regulatory shifts and seeks greener alternatives, MustGrow Biologics Corp. stands ready to capitalize on this momentum, leveraging its unique AITC technology and newly secured financial resources to drive growth and innovation.